Biological E
Highly Engaged Employees
Highly Engaged EmployeesBlood & Organ Banks · India · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
no 35 Road Jubilee Hls, Dr.B R Ambedkar ...Phone Number
+91 4071216000Website
www.biologicale.comRevenue
$693.7 MillionIndustry
ZI Rank: 5
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
5
8
10
6
10
5
About Biological E
Biological E. Ltd. (BE) is a leading vaccine and pharmaceutical company. The company produces a range of critical vaccines and has been an active partner in the National Immunization Program of India. Biological E Limited is headquartered in Telangana, India and was established in 1953.Explore more
Biological E Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Biological E your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if Biological E has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Check out if Biological E is spiking on competitors!
Funding: Get notified immidiatlly once Biological E has new funding data
Click to see if Biological E had a recent Job posting/layoffs
Earning: See what the market has to say on Biological E recently announced quarterly report
Biological E, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Biological E
Product Launch: Get notified when Biological E launches new products
Recommended Actions
Reach out to Masked Content who joined Biological E as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Biological E is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Biological E is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Biological E.
Biological E financials insights
Gather financial insights about Biological E, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2020
Grant
$5M
Biological E Tech Stack
A closer look at the technologies used by Biological E
See more technologies
Most Recent Scoops
Person-Based
Partnership, Pharmaceuticals
Person-Based
Quality Assurance, Laboratory Operations
Person-Based
Compliance, Quality Management, Manufacturing Operations
Hiring Plans
Biological E has more open roles in Finance than it has had at any time in the past 12 months. Areas of expertise include: Tax Risk Management, Tax Returns, International Taxation, Tax Planning, Regulatory Affairs, Tax Compliance, and Indirect Tax.
Hiring Plans
Person-Based
Pharmaceuticals, Public Health
Biological E News & Media
Japan's Takeda in regulatory talks to launch dengue vaccine in India
The Japanese drugmaker plans to scale up the production of its dengue vaccine Qdenga through a partnership with Indian vaccine maker Biological E., the companies said earlier in the day. (Source: The Economic Times Healthcare and Biotech News)Takeda, Biological E enter manufacturing pact to produce 50 million doses of Dengue vaccine
Japanese drug giant Takeda has partnered with Indian vaccine maker Biological E (BE) to manufacture its Dengue vaccine. BE will increase its manufacturing capacity to up to 50 million doses a year, supporting Takeda's goal to produce 100 million doses annually by 2030. The collaboration leverages Takeda's existing facility in Germany and its partnership with IDT Biologika GmbH. (Source: The Economic Times Healthcare and Biotech News)Takeda Accelerates Access to its Dengue Vaccine Through 'Make in India' Manufacturing Partnership with Biological E.
New strategic partnership will scale-up manufacturing capacity to support global supply of dengue vaccine and expands Takeda's footprint in vaccine manufacturing. The strategic partnership will deliver potentially up to 50 million doses per year by 2030 to address global public health need. Dengue is a global public health threat, and we are committed to helping reduce the burden of disease through ongoing efforts to expand our supply capacity for our dengue vaccine. SINGAPORE, Feb. 27, 2024Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas
CAMBRIDGE, Mass. & HYDERABAD, India--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) and Biological E. Limited (BE), a leading India-based Vaccines and Pharmaceutical Company, today announced a strategic partnership to accelerate access to QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) (TAK-003) multi-dose vials (MDVs). These doses will ultimately be made available for procurement by governments in endemic countries by 2030 at the latest to support National Immunization Programs. MDVs off
Read more news
Top Blood & Organ Banks Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Biological E
Sign Up For FreeTo access detailed company insights
Biological E. Ltd. (BE) is a leading vaccine and pharmaceutical company. The company produces a range of critical vaccines and has been an active partner in the National Immunization Program of India. Biological E Limited is headquartered in Telangana, India and was established in 1953.... Read More
